NeoGenomics Historical Financial Ratios
| NEO Stock | USD 16.98 0.49 2.97% |
NeoGenomics is lately reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 70.22 will help investors to properly organize and evaluate NeoGenomics financial condition quickly.
NeoGenomics |
About NeoGenomics Financial Ratios Analysis
NeoGenomicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NeoGenomics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NeoGenomics financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NeoGenomics history.
NeoGenomics Financial Ratios Chart
Add Fundamental
Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to NeoGenomics. There are two different methods for calculating NeoGenomics invested capital: operating approach and financing approach. Understanding NeoGenomics invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most ratios from NeoGenomics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NeoGenomics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.At this time, NeoGenomics' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 5th of January 2025, Average Inventory is likely to grow to about 516.6 K, while Price To Sales Ratio is likely to drop 3.75.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 85.72 | 80.98 | 72.88 | 70.22 | PTB Ratio | 1.15 | 2.16 | 2.48 | 2.36 |
NeoGenomics fundamentals Correlations
Click cells to compare fundamentals
NeoGenomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NeoGenomics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 13.15 | 8.45 | 2.25 | 3.43 | 3.95 | 3.75 | |
| Days Sales Outstanding | 87.74 | 84.5 | 85.72 | 80.98 | 72.88 | 70.22 | |
| Book Value Per Share | 6.39 | 9.24 | 8.03 | 7.5 | 6.75 | 7.09 | |
| Free Cash Flow Yield | (0.004727) | (0.0222) | (0.0844) | (0.0151) | (0.0136) | (0.0143) | |
| Operating Cash Flow Per Share | 0.0134 | (0.22) | (0.53) | (0.0156) | (0.014) | (0.0133) | |
| Stock Based Compensation To Revenue | 0.023 | 0.0464 | 0.0484 | 0.0416 | 0.0375 | 0.0393 | |
| Ev To Sales | 13.13 | 9.06 | 2.93 | 3.89 | 4.47 | 4.25 | |
| Free Cash Flow Per Share | (0.25) | (0.76) | (0.78) | (0.24) | (0.28) | (0.27) | |
| Roic | 7.31E-4 | (0.003372) | (0.0904) | (0.066) | (0.0759) | (0.0796) | |
| Inventory Turnover | 8.76 | 12.71 | 13.26 | 14.37 | 16.52 | 21.05 | |
| Net Income Per Share | 0.0384 | (0.0696) | (1.16) | (0.7) | (0.63) | (0.6) | |
| Days Of Inventory On Hand | 41.68 | 28.73 | 27.53 | 25.41 | 22.87 | 17.59 | |
| Payables Turnover | 10.36 | 16.59 | 15.69 | 17.07 | 15.36 | 16.13 | |
| Sales General And Administrative To Revenue | 0.32 | 0.46 | 0.48 | 0.41 | 0.47 | 0.74 | |
| Research And Ddevelopement To Revenue | 0.0185 | 0.0452 | 0.0595 | 0.0462 | 0.0531 | 0.0744 | |
| Capex To Revenue | 0.0655 | 0.13 | 0.0606 | 0.0486 | 0.0559 | 0.0531 | |
| Cash Per Share | 2.73 | 4.3 | 3.53 | 3.31 | 2.98 | 3.13 | |
| Pocfratio | 4.0K | (153.17) | (17.39) | (1.0K) | (935.77) | (888.98) | |
| Interest Coverage | (0.3) | (1.97) | (101.66) | (15.6) | (17.94) | (17.04) | |
| Capex To Operating Cash Flow | 19.93 | (2.4) | (0.47) | (14.72) | (13.25) | (12.59) | |
| Pfcf Ratio | (211.53) | (45.05) | (11.85) | (66.13) | (59.52) | (56.54) | |
| Days Payables Outstanding | 35.24 | 22.0 | 23.26 | 21.39 | 24.59 | 23.36 | |
| Income Quality | 0.35 | 3.2 | 0.46 | 0.0222 | 0.0255 | 0.0243 | |
| Roe | 0.006009 | (0.007532) | (0.14) | (0.0934) | (0.11) | (0.1) | |
| Ev To Operating Cash Flow | 4.0K | (164.24) | (22.66) | (1.2K) | (1.1K) | (1.0K) | |
| Pe Ratio | 1.4K | (490.37) | (7.96) | (23.08) | (20.78) | (19.74) | |
| Return On Tangible Assets | 0.0208 | 0.006354 | (0.009271) | (0.18) | (0.11) | (0.1) | |
| Ev To Free Cash Flow | (211.15) | (48.3) | (15.44) | (74.9) | (67.41) | (64.04) | |
| Earnings Yield | 7.14E-4 | (0.002039) | (0.13) | (0.0433) | (0.039) | (0.0409) | |
| Intangibles To Total Assets | 0.34 | 0.52 | 0.54 | 0.53 | 0.48 | 0.35 | |
| Net Debt To E B I T D A | (0.3) | 5.68 | (4.42) | (15.29) | (13.76) | (13.07) | |
| Current Ratio | 6.13 | 7.81 | 6.73 | 6.2 | 5.58 | 5.86 | |
| Tangible Book Value Per Share | 3.34 | 1.16 | 0.54 | 0.36 | 0.33 | 0.27 | |
| Receivables Turnover | 4.16 | 4.32 | 4.26 | 4.51 | 5.18 | 5.13 | |
| Graham Number | 2.35 | 3.8 | 14.49 | 10.88 | 9.79 | 10.28 |
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
| 0.93 | VALN | Valneva SE ADR | PairCorr |
| 0.85 | DRRX | Durect | PairCorr |
| 0.73 | EQ | Equillium | PairCorr |
| 0.7 | ME | 23Andme Holding | PairCorr |
| 0.64 | DNTH | Dianthus Therapeutics | PairCorr |
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 0.104 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.